報價延遲最少15分鐘:2025/11/04 16:08 EST
盤後時段
|
||||
|
4.83 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.83
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.38/-0.30
|
|
企業價值
1.77B
|
| 資產負債 |
|
每股賬面淨值
1.09
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
7.87M
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/11/04 16:08 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan. |
